Search results for "clinical trials as topic"

showing 10 items of 313 documents

Health benefits of different sport disciplines for adults: systematic review of observational and intervention studies with meta-analysis

2015

The aim was to assess the quality and strength of evidence for the health benefits of specific sport disciplines. Electronic search yielded 2194 records and the selection resulted in 69 eligible studies (47 cross-sectional, 9 cohort, 13 intervention studies). 105 comparisons between participation and non-participation groups in 26 different sport disciplines were reported. Moderately strong evidence showed that both running and football improve aerobic fitness and cardiovascular function at rest, and football reduces adiposity. Conditional evidence showed that running benefits metabolic fitness, adiposity and postural balance, and football improves metabolic fitness, muscular performance, p…

AdultMaleGerontologymedicine.medical_specialtyHealth Statusmedia_common.quotation_subjectHealth BehaviorPhysical Therapy Sports Therapy and RehabilitationHealth PromotionFootballHealth benefitsRunningRisk FactorsSoccerPostural BalanceHumansMedicineAerobic exerciseOrthopedics and Sports MedicineQuality (business)Prospective StudiesSwimmingmedia_commonClinical Trials as Topicbusiness.industryGeneral MedicineObservational Studies as TopicPhysical FitnessMeta-analysisAthletic InjuriesCohortPhysical therapyFemaleObservational studybusinessSportsBritish Journal of Sports Medicine
researchProduct

Quantitative sensory testing: a comprehensive protocol for clinical trials.

2004

We have compiled a comprehensive QST protocol as part of the German Research Network on Neuropathic Pain (DFNS) using well established tests for nearly all aspects of somatosensation. This protocol encompasses thermal as well as mechanical testing procedures. Our rationale was to test for patterns of sensory loss (small and large nerve fiber functions) or gain (hyperalgesia, allodynia, hyperpathia), and to assess both cutaneous and deep pain sensitivity. The practicality of the QST protocol was tested in 18 healthy subjects, 21-58 years, half of them female. All subjects were tested bilaterally over face, hand and foot. We determined thermal detection and pain thresholds including a test fo…

AdultMalePain Thresholdmedicine.medical_specialtyAudiologyClinical ProtocolsThreshold of painmedicineHumansPain MeasurementClinical Trials as TopicReproducibility of ResultsSensory lossHypoesthesiaMiddle AgedAnesthesiology and Pain MedicineAllodyniaHyperalgesiaResearch DesignAnesthesiaNeuropathic painHyperalgesiaHyperpathiaBody regionFemalemedicine.symptomPsychologyEuropean journal of pain (London, England)
researchProduct

Strategy for Long-Term Surveillance at the German Childhood Cancer Registry - an Update

2011

Background The objective of this paper is to provide information about the quality (e.g. completeness, response) of long-term surveillance in German paediatric oncology and haematology based on the structures implemented by the German Childhood Cancer Registry (GCCR). Methods The GCCR contacts parents or patients to collect and update information on a minimal set of follow-up health status data (e.g. late relapses, subsequent neoplasms, current address) and exchanges this information regularly with the appropriate clinical trials. Results Between 2006 and 2010, GCCR approached a total of about 20,000 patients (contact at the age of 16 years, inquiry concerning the health status) in the cont…

AdultMalePediatricsmedicine.medical_specialtyAdolescentDatabases FactualLymphomaCross-sectional studyHealth StatusMEDLINECentral Nervous System NeoplasmsCohort StudiesGermanYoung AdultCause of DeathGermanyNeoplasmsHumansMedicineRegistriesSurvivorsYoung adultChildClinical Trials as TopicChildhood Cancer RegistryLeukemiabusiness.industryMiddle AgedLong-Term CareSurvival Analysislanguage.human_languageClinical trialLong-term careCross-Sectional StudiesChild PreschoolPopulation SurveillanceFamily medicinePediatrics Perinatology and Child HealthQuality of LifelanguageFemalebusinessCohort studyKlinische Pädiatrie
researchProduct

Helicobacter pylori Infection as a Triggering Factor of Attacks in Patients with Hereditary Angioedema

2007

  Udgivelsesdato: 2007-Jun BACKGROUND: Helicobacter pylori infection is considered among the causative factors of urticaria and angioedema. Having conducted a study on 65 patients, Hungarian authors reported in 2001 that successful eradication of H. pylori is followed by a significant reduction in the number of attacks in patients with hereditary angioedema (HAE). The present study aimed to reinvestigate the relationship between H. pylori infection and the attack rate in the framework of an international collaborative study. MATERIALS AND METHODS: Within the framework of the PREHAEAT project launched by the European Union, further 152 patients were studied in seven collaborating centers, an…

AdultMalePeptic UlcerHelicobacter pylori infectionmedicine.medical_specialtyAdolescentImmunologyAttack ratemacromolecular substancesHelicobacter InfectionsDisease severityInternal medicinemedicineImmunology and AllergyHumansmedia_common.cataloged_instanceIn patientAttack frequencyAngioedemaEuropean unionChildAgedmedia_commonClinical Trials as TopicHelicobacter pyloribiologyAngioedemabusiness.industryGastroenterologyGeneral MedicineMiddle AgedHelicobacter pylorimedicine.diseasebiology.organism_classificationInfectious DiseasesChild PreschoolGastritisHereditary angioedemaImmunologyFemalemedicine.symptombusinessHelicobacter
researchProduct

Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease

1988

In a six-month multicenter feasibility and safety study, 20 patients, who all had a congenital deficiency of alpha-1-protease inhibitor (A1PI) of the PiZ phenotype accompanied by a chronic obstructive lung disease, were treated with human-plasma-derived A1PI. A weekly dose of 60 mg/kg, administered intravenously, was shown to be sufficient to maintain patient serum levels above the threshold limit of 35 percent, the serum level of healthy persons of the MZ phenotype. This is supposed to be the minimal effective level for protection against the elastolytic attack of the lung and, therefore, satisfies one of the most important criteria of feasibility of long-term replacement therapy. The glob…

AdultMalealpha 1-Antitrypsin DeficiencymedicineHumansLung Diseases ObstructiveInfusions IntravenousAgedRadial immunodiffusionClinical Trials as TopicLungPancreatic Elastasebiologybusiness.industryBlood ProteinsGeneral MedicineMiddle AgedOuchterlony double immunodiffusionTrypsinmedicine.diseaseAlpha-1 Protease Inhibitor DeficiencyObstructive lung diseasePhenotypemedicine.anatomical_structureImmunologybiology.proteinFemaleAntibodyLung Volume MeasurementsbusinessNephelometrymedicine.drugThe American Journal of Medicine
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

LDL size: does it matter?

2004

The atherogenic lipoprotein phenotype is characterised by a moderate increase in plasma triglycerides, a decrease in high density lipoprotein cholesterol and the prevalence of smaller denser low density lipoprotein particles. The prevalence of this partially inheritable phenotype is approximately 30% and is a feature of the metabolic syndrome associated with an increased risk for cardiovascular events. The predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the adult treatment panel (ATP) III.

AdultMalemedicine.medical_specialtyArteriosclerosisCoronary DiseaseCohort Studieschemistry.chemical_compoundHigh-density lipoproteinSex FactorsRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusPrevalenceAnimalsHumansatherogenic lipoprotein phenotypeProspective Studiescoronary heart diseaseRisk factorsmall dense LDLTriglyceridesAgedHypolipidemic AgentsMetabolic SyndromeClinical Trials as Topicdiabetesbusiness.industryCholesterolSmokingAge FactorsGeneral MedicineCholesterol LDLAtherogenic lipoprotein phenotypeMiddle Agedmedicine.diseasePhenotypeLipoproteins LDLEndocrinologyLogistic ModelsPhenotypechemistryLow-density lipoproteinFemaleMetabolic syndromeInsulin ResistancebusinessSwiss medical weekly
researchProduct

Dose-response relationships and plasma concentrations of digitalis glycosides in man.

1978

An inter-individual, randomized, double-blind study of digitoxin (Dt) and β-acetyl digoxin (D) was performed in 120 healthy male volunteers. Groups of 10 persons each received orally D 0, 0.1, 0.2, 0.3, 0.4, 0.5 or 0.6 mg and Dt 0.04, 0.08, 0.12, or 0.16 mg daily for 7 days; Loading doses were given for the first three days. Plasma levels were measured with an86Rb-erythrocyte assay 24 h after the last dose. ECG, carotid artery pulse and phonocardiogram were recorded prior to (b) and 24 h after (a) the last dose. QTc, amplitude of T-waves in V2 to V6, electromechanical systole (QS2c) and left ventricular ejection time (LVETc) were measured. The differences between a and b (Δ-values) reflect …

AdultMalemedicine.medical_specialtyDigoxinTime FactorsDigoxinDigitoxinQT intervalElectrocardiographyDigitoxinDouble-Blind MethodInternal medicinemedicineHumansPharmacology (medical)Pharmacologychemistry.chemical_classificationClinical Trials as TopicDose-Response Relationship DrugChemistryPulse (signal processing)GlycosideDigitalis GlycosidesHeartGeneral MedicinePlasma levelsEndocrinologySystolic time intervalsPlasma concentrationmedicine.drugEuropean journal of clinical pharmacology
researchProduct

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

1986

Forty patients with Graves' ophthalmopathy stages III-V were divided into two groups in a random manner according to their year of birth. Group I received prednisone in decreasing dosage. Group II received prednisone at a comparable dosage and ciclosporin. Steroids were discontinued after 10 weeks in the two groups. In the patients of group II, ciclosporin was continued over 12 months. The therapeutic effect was assessed by an activity score based on subjective and objective symptoms (computerized tomography and sonography of the orbit, Hertel values, clinical findings). All signs of endocrine ophthalmopathy improved significantly in both groups (P less than 0.01 in group I; P less than 0.0…

AdultMalemedicine.medical_specialtyEye DiseasesClinical BiochemistryVisual AcuityCyclosporinsBiochemistryGastroenterologylaw.inventionGraves' ophthalmopathyPharmacotherapyRandomized controlled triallawPrednisoneInternal medicinemedicineHumansProspective StudiesProspective cohort studyClinical Trials as TopicDose-Response Relationship Drugbusiness.industryTherapeutic effectGeneral MedicineMiddle AgedCiclosporinmedicine.diseaseGraves DiseaseClinical trialEndocrinologyPrednisoneDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesEuropean journal of clinical investigation
researchProduct